European CHMP recommends license extension of Recarbrio (imipenem / cilastatin / relebactam)

The license extension is for treatment of adults with hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP), and treatment of bacteraemia that occurs in association with, or is suspected to be associated with HAP or VAP.

Source:

European Medicines Agency